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Abstract
Objectives. Histological examination of pathological tendon generally does not reveal signs of inflamma-
tion. However, the inflammatory cytokine IL-6 has been shown to be expressed in ruptured rotator cuff
tendon. The aim of this study was to investigate the expression of IL-6 family members in painful posterior
tibialis tendon (PTT) and in painful and ruptured Achilles tendon (AT) compared with normal tendon.
Methods. AT samples were obtained from cadavers (normal) or from patients undergoing surgical
procedures to treat chronic painful tendinopathy or ruptured tendon. PTT samples were obtained from
patients undergoing surgery for other reasons (normal) and from patients with PTT dysfunction (painful).
Total RNA was extracted and mRNA expression was analysed by quantitative real-time PCR.
Results. Collagen type I a-chain I (COL1A1) expression was increased in both painful PTT and AT
compared with normal. Ciliary neurotrophic factor levels were increased in painful PTT only. In the painful
AT, cyclooxygenase-2 (COX2) and IL-6 expression increased compared with normal. In the ruptured AT,
levels of VEGF A, COX2, oncostatin-M, leukaemia inhibitory factor and IL-6 expression were higher
compared with both normal and painful AT. IL-6R expression decreased in both painful and ruptured
AT compared with normal.
Conclusion. Painful AT and PTT show different expression patterns, indicating a substantial difference
between those two tendinopathies. Inflammatory markers are up-regulated in painful and particularly in
ruptured AT, pointing towards a role of inflammation not only in rupture healing, but also in Achilles
tendinopathy.
Key words: gene expression, tendinopathy, tendon rupture, OSM, LIF, CNTF, IL-6, Achilles tendon, posterior
tibialis tendon.
Introduction
Tendinopathy, characterized by chronic tendon pain,
swelling and impaired performance, is a common syn-
drome in both recreational and elite athletes as well as
in the general population. Although its aetiology remains
poorly understood, tendinopathy is considered to be a
primarily degenerative condition, as histological examin-
ation of pathological tendon generally does not detect in-
flammatory cells in or around the lesion [1]. However,
inflammation may still play a role in the early initiation of
the disease, as some studies indicate that acute overload-
ing may induce an inflammatory response in tendon
tissue.
Fatigue loading of the rat patellar tendon in vivo caused
structural damage, accompanied by increased mRNA
expression of the inflammatory cytokine IL-1b [2].
Furthermore, cyclic stretching of cultured human tendon
fibroblasts increased the production of the inflammatory
mediators prostaglandin E2 (PGE2), cyclooxygenase-1
and cyclooxygenase-2 (COX2) [3], while COX2 expression
was up-regulated in the ruptured rat Achilles tendon (AT)
when allowed free mobilization post-surgery [4]. IL-6, a
cytokine with a central role in inflammation and tissue
injury has also been shown to be secreted at an increased
level upon cyclical stretching of human tendon fibroblasts
[5]. In vivo, an intense running bout led to increased IL-6
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AT in humans [6].
Further studies have suggested that inflammatory cyto-
kines and mediators may play a role during the progres-
sion of tendinopathic conditions, as they have also been
detected in painful and ruptured tendon [1, 7]. COX2, also
known as PG-endoperoxide synthase 2, leads to
increased synthesis of pro-inflammatory PGs such as
PGE2. Comparing tissue sections of tendinopathic and
healthy human patellar tendon, immunohistochemical
staining has revealed that the percentage of COX2 immu-
nopositive cells was more than twice as high in the tendi-
nopathic samples [1]. This also coincided with an
increased secretion of PGE2 by cultured fibroblasts from
tendinopathic tissue [1]. IL-6 mRNA has been shown to be
highly expressed in ruptured human rotator cuff tendon,
with immunohistochemical analysis indicating that the
positive staining was mainly in proliferative vessels and
to a lesser extent in fibroblasts [7]. Unfortunately, these
samples were not compared with healthy controls.
Furthermore, it is unknown if and how other members of
the IL-6 family are expressed in response to tendinopathic
changes or tendon rupture. The family of IL-6-type cyto-
kines includes IL-6, IL-11, oncostatin M (OSM), leukaemia
inhibitory factor (LIF), ciliary neurotrophic factor (CNTF)
and cardiotrophin-1, which all signal through the
common receptor subunit gp130 [8].
The aim of this study was to investigate the gene
expression of IL-6 and other members of the IL-6 family
in painful and ruptured human tendon compared with
healthy controls. Expressions of COX2 and other genes
known to be up-regulated in tendinopathy [collagen type 1
a-chain 1 (COL1A1) and VEGF A] were also investigated.
We analysed samples from normal, painful and ruptured
AT as well as normal and painful posterior tibialis tendon
(PTT) to test whether similar patterns of gene expression
are observed in similar pathologies of different tendon
types.
Materials and methods
Tendon specimens
Morphologically normal AT specimens from the mid-
region 56cm from the insertion were obtained post-
mortem within 954h from nine males [age 45.3 (16.4)
years] with no known history of tendon problems. Painful
AT samples were obtained from the lesion site from 20
patients [13 males and 7 females; age 47.3 (7.2) years]
undergoing surgical procedures to treat chronic painful
Achilles tendinopathy of at least 6 months duration.
Ruptured AT samples were obtained from the site of rup-
ture from 18 patients [14 males and 4 females; age 46.3
(12.3) years] undergoing surgical repair of the damaged
AT. Morphologically normal PTT specimens were ob-
tained from 10 patients [6 males and 4 females; age
47.5 (11.7) years] undergoing unrelated surgery (e.g.
osteosarcoma). Painful PTT samples were obtained from
the lesion site from 20 patients [6 males and 14 females;
age 53.9 (11.9) years] clinically classified to have Stage II
dysfunction (correctable without fixed deformity) and
undergoing surgical repair by tendon transfer of the neigh-
bouring flexor digitorum longus tendon to restore func-
tional support of the foot arch. Both normal and painful
PTT tissues were harvested from the region that wraps
around the medial malleolus. The study had local ethics
committee approval (Cambridge Research Ethics
Committee and Joint Royal National Orthopaedic
Hospital/Institute of Orthopaedics and Musculoskeletal
Science (RNOH/IOMS) Research Ethics Committee), and
appropriate informed consent was obtained from the
patients or their relatives.
Gene expression analysis
Total RNA was isolated from frozen tissue samples by a
modified Tri-Spin protocol as described previously [9].
The concentration of RNA was estimated using a
NanoDrop spectrophotometer and the absorbance ratio
A260/A280 was 1.82 (0.15) for the AT and 1.60 (0.07) for
the PTT specimens [mean (S.E.)]. cDNA was prepared
using SuperScript II (Invitrogen, UK) and primed using
random hexamers. The mRNA levels of eight genes of
interest were quantified using quantitative real-time
PCR: COL1A1, VEGF, COX2, OSM, LIF, CNTF, IL-6 and
IL-6 receptor (IL-6R). 18S ribosomal RNA was used
to check the quality of the RNA. Topo-1 and eukaryotic
initiation factor 4A-II (EIF4A2) were used as house-
keeping genes. Specific primers were obtained from
Applied Biosystems (Paisley, UK) and PrimerDesign
(Southampton, UK) or designed using Primer Express
1.0 software (Applied Biosystems, Warrington, UK) and
the Roche Universal ProbeLibrary Assay Design Centre
(for primer and probe sequences see supplementary
data available at Rheumatology Online). The relative quan-
titation of genes was performed using the 7500 Real-Time
PCR System (Applied Biosystems, Paisley, UK).
Conditions for the PCR were 2min at 50C, 10min at
95C and then 45 cycles, each consisting of 15s at
95C and 1min at 60C. The cycle number (Ct) at which
amplification entered the exponential phase was deter-
mined. Gene expression data are presented as
2
Ct=2[Ct gene of interest  ((Ct EIF4A2 + Ct
topo-1)/2)], normalizing the expression of the genes of
interest to the mean Ct of topo-1 and EIF4A2.
Statistical analyses
As we did not detect any gender differences using a
two-way analysis of variance (ANOVA), results for males
and females are presented together. To detect differences
in gene expression between groups, a MannWhitney
U-test was performed on the 2
Ct values using SPSS
16.0 for Windows. For all statistical tests, significance
was established at P40.05.
Results
COL1A1 and CNTF expression were significantly elevated
14- and 2.9-fold, respectively, in painful PTT compared
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sion significantly increased 9-fold compared with controls.
Although the median CNTF level was 3.9-fold higher in
painful than in normal AT, this difference was not signifi-
cant. COX2 and IL-6 expression significantly increased
2-fold and 6.3-fold, respectively, in painful compared
with normal AT, while IL-6R expression decreased
3.6-fold. In the ruptured AT, VEGF, COX2, OSM, LIF and
IL-6 expression were all significantly higher compared
with both normal AT (4.1-, 11-, 39-, 20- and 180-fold, re-
spectively) and painful AT (7.2-, 5.6-, 31-, 14- and 28-fold,
respectively). IL-6R expression in the ruptured AT was
2.7-fold less compared with normal (Fig. 1A).
Discussion
The expression of some IL-6 family members was
found to be up-regulated in pathological tendon.
However, contrary to our expectation, painful AT and
PTT showed different expression patterns, indicating a
substantial difference between those two tendinopathies.
The up-regulation of inflammatory markers in ruptured
AT might point towards a role of inflammation in rupture
healing. However, inflammatory markers were also
up-regulated in painful AT, suggesting a potential role of
inflammation in Achilles tendinopathy also. In contrast, the
increase in expression of IL-6 and COX2 found in the
FIG.1Expression of mRNA in (A) normal, painful and ruptured AT and (B) normal and painful PTT. Values are normalized
to the mean of EIF4A2 and topo-1. Data are presented as box-and-whisker plots. The median is represented by the line
within the box, while the box extends from the 25th to the 75th percentile. The whiskers show the highest and lowest
values. *Significantly different from control specimens; **significant difference between painful and ruptured specimens
(P40.05; MannWhitney U-test).
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IL-6 family expression in tendon pathologypainful AT does not occur in the painful PTT. Such a find-
ing indicates that the inflammatory response may not
simply be a cell response to degeneration or inflammation,
but could also be influenced by differences in gross
mechanical loading of the AT and PTT. The mechanical
properties of the AT have been shown to be altered by
tendinopathy, leading to lower tendon stiffness and higher
in vivo strains during isometric plantar flexion compared
with healthy AT [10]. Previous studies have demonstrated
that the concentration of IL-6 and COX2 rises with
increased mechanical strain [3, 6]. Hence the higher
strains perceived by cells in tendinopathic AT may be
the cause of the up-regulation of IL-6 and COX2 seen in
the painful AT in our study. In contrast, the PTT appears
to lengthen permanently with tendinopathy, resulting
in a loss of support of the foot arch (A. Robinson, con-
sultant orthopaedic surgeon, Addenbrooke’s Hospital,
Cambridge, personal observation). This elongation likely
reduces the mechanical strain on the cells during loading
and may explain the lack of inflammatory response in this
tendon. The down-regulation of IL-6R in painful and rup-
tured AT could be a response to high levels of IL-6.
The expression of the IL-6 family member’s OSM and
LIF was increased in ruptured compared with normal and
painful AT. It is unknown whether these changes pre-
ceded the rupture or were a result of the rupture and fol-
lowing healing process. Both OSM and LIF have been
shown to stimulate release and suppress synthesis of pro-
teoglycans in articular cartilage [11, 12].
Similarly CNTF, which was up-regulated in painful PTT,
has also been shown to inhibit proteoglycan synthesis,
although without affecting proteoglycan release [12].
One might assume that OSM, LIF and CNTF might func-
tion in a similar way in tendon, thereby decreasing proteo-
glycan content. However, this seems surprising, since
GAG content and mRNA expression of the proteoglycans
aggrecan and biglycan has been shown to increase in AT
tendinopathy [13] while the expression of decorin either
increased [14] or decreased [13] in AT rupture.
Collagen metabolism has also been shown to be influ-
enced by IL-6 and OSM. Collagen degradation is stimu-
lated in tendon tissue treated with OSM in combination
with IL-1a [15] and in cartilage tissue treated with the
combination of IL-1a and either IL-6 (in the presence of
its soluble receptor) or OSM [16]. However, IL-6 can also
stimulate collagen synthesis, as IL-6 injections led to an
increased concentration of a procollagen marker in the
peritendinous space around the human AT [17]. An
increased COL1A1 expression is a common response to
tendinopathy [9, 18], and one we confirm in this study,
showing an increased expression in both painful AT and
PTT. Such a response seems to indicate an attempt of the
tendon to restore normal tissue composition and function.
An increase in expression of the angiogenic factor
VEGF has also been described as a common sign of
pathological tendon, as it is critical for neovascularization
that usually does not occur in healthy adult tendon
[1921]. However, VEGF expression is highly variable
in tissue samples of painful tendinopathy [19, 21],
suggesting that expression might depend on the stage
of the disease. A study on patellar tendinopathy showed
that the subset of patients demonstrating VEGF expres-
sion suffered from tendinopathy for a considerably shorter
time period than the patients with no detectable VEGF
[21]. This indicates that VEGF might only be up-regulated
early in the onset of the disease or the healing process,
and might explain why we found VEGF to be up-regulated
in ruptured AT but not in painful AT or PTT.
Limitations of the study and potential future directions
The extent to which the altered gene expression of IL-6
family members in painful and ruptured tendon is trans-
lated into protein remains to be established.
Immunohistochemistry could determine where in the
tissue those proteins are expressed, focusing particularly
on vascular expression, as blood vessels have been
shown to be a major source of IL-6 expression in ruptured
tendon [7] and neovascularization has been linked to ten-
dinopathy. Also, the response of the tissue could be af-
fected by gender or age, e.g. mRNA expression levels
tend to decrease with age (see supplementary data avail-
able at Rheumatology Online).
Conclusion
We have shown that IL-6 family members are expressed
in tendon and that they are up-regulated in tendon path-
ology. However, as IL-6 has been attributed both pro- and
anti-inflammatory function [22], expression of IL-6 and
COX2 in pathological tendon does not necessarily indi-
cate a state of inflammation. The role and function of
the IL-6 family members in tendons needs to be further
clarified. It remains to be established whether the differ-
ence in gene expression between pathological AT and
PTT is due to differences in loading, tendon structure or
composition or reflects a difference in the type, progres-
sion or healing of tendinopathy. Given those differences, it
is possible that the success of different treatment options
may depend on the anatomical site of the tendinopathy.
Rheumatology key messages
. IL-6 family members are expressed in tendon and
up-regulated in tendon pathology.
. Tendinopathic Achilles and PTT show different gene
expression patterns.
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